Italian industry responds to govt on SSN pressures
This article was originally published in Clinica
As Clinica went to press, Italian medical technology industry association Assobiomedica was preparing to issue a formal response to a speech made by vice-minister for the economy Mario Baldassarri at last week's DiaBioTech conference.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.